Sanofi (NYSE:SNY) reports positive top-line results from a pivotal Phase III trial for Aubagio, its investigational teriflunomide medication for the treatment of relapsing multiple sclerosis. Annual relapse rates were significantly reduced in patients using the drug.
Don’t Miss: 8 HUGE Winning and Losing Stocks in May.
Shares of PharmAthene (AMEX:PIP) gain more than one fourth of their value Friday, following news that a United States court upheld a ruling that awards it a portion of profits received by Siga Technologies (NASDAQ:SIGA) from its smallpox antiviral drug, ST-246. This decision is the most recent event in what is now a long running legal duel between the two firms.
Sales of Eylea, which is Regeneron’s (NASDAQ:REGN) big cash cow, might be pulling back according to Cowen’s Phil Nadeau, referring to its most recent physician survey. The drug represents the firm’s treatment for a leading cause of blindness in the elderly; growth in the number of patients using the med slowed from 155 percent in the January – March period, to only 22 percent from March to May. Cowen notes the deceleration, and remarks that the stock might be ‘rich at these levels’.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.